Lionel Perrier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lionel Perrier has a total of 567 co-authors. Here are the top co-authors by number of shared publications:
Magali Morelle
Centre Léon Bérard, CNRS, Université Lumière Lyon 2, Université Jean Monnet Saint-Etienne, Emlyon Business School, GATE, Lyon, France
15 shared publications- Béatrice Fervers
Centre Léon Bérard, 69008 Lyon, France
8 shared publications M. Morelle
8 shared publicationsDavid Pérol
Direction of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France
6 shared publications- Georges Noel
RT Department, Institut de cancérologie Strasbourg Europe (ICANS), 17 rue Albert Calmette, Strasbourg, France; Medicine Strasbourg University, 4 Rue Kirschleger, 67000 Strasbourg, France
6 shared publications - Valentin Calugaru
Department of Radiation Oncology, Proton Therapy Centre, Institut Curie , Orsay, Paris, 75005
6 shared publications
Latest Publications
- Open Access
Methods and evidence in economic evaluations of modern radiotherapy: a systematic mapping review protocol
Introduction: Modern radiotherapy modalities have increased treatment precision and clinical effectiveness. However, the economic evidence that underpins their adoption is highly heterogeneous, with substantial variation in costing methods, data sources, analytic designs (trial-based, real-world/observational and decision-analytic modelling), perspectives and the treatment of uncertainty. We propose a systematic mapping review to characterise the peer-reviewed evidence base and identify methodological gaps relevant to health technology assessment and policy-making. This systematic mapping review aims to: (1) systematically catalogue the published, peer-reviewed evidence and the methodological approaches used in economic evaluations of modern radiotherapy; (2) identify methodological trends, including the uptake and implementation of value of information analysis and (3) highlight evidence gaps by tumour type, geographical region and methodological approach. Methods and analysis: Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, we searched PubMed (MEDLINE), Embase, Scopus, Web of Science Core Collection and EconLit for economic evaluations of radiotherapy published from 2005 onwards, with an initial search on 24 February 2026 and a planned search update before synthesis. Study selection is ongoing; extraction and quality appraisal in duplicate have not been undertaken and no results are reported. Reporting completeness, methodological limitations and uncertainty will be appraised as three separate dimensions using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist, the Bias in Economic Evaluation (ECOBIAS) checklist and the TRansparent Uncertainty ASsessmenT (TRUST) framework, applied descriptively and not combined into a single quality score. Methodological information will be extracted, including model structure (eg, Markov model), analytical perspective (eg, healthcare payer), time horizon, costing approach (eg, diagnosis-related group (DRG)-based) and utility measurement (eg, EQ-5D). The methods used to assess uncertainty will be mapped for all studies, with the ECOBIAS checklist and the TRUST framework only applied to decision-analytic model-based evaluations. Findings will be synthesised descriptively as an evidence gap map and visualised as heat maps and bubble plots. A conceptual co-occurrence network, analysed in R with visualisation in VOSviewer, will map how modalities, tumour sites and economic characteristics cluster across studies. No meta-analysis is planned, given the expected heterogeneity of our findings. Ethics and dissemination: This review does not require ethical approval, as it will use data from previously published studies. The results will be disseminated through peer-reviewed publications, conference presentations and open-access releases of data extraction files and visual maps in the Open Science Framework (OSF). Registration: This review protocol was prospectively registered (9 February 2026) in the OSF Registries (DOI: 10.17605/OSF.IO/6W2TJ).
Open AccessMethods and evidence in economic evaluations of modern radiotherapy: a systematic mapping review protocol
Introduction: Modern radiotherapy modalities have increased treatment precision and clinical effectiveness. However, the economic evidence that underpins their adoption is highly heterogeneous, with substantial variation in costing methods, data sources, analytic designs (trial-based, real-world/observational and decision-analytic modelling), perspectives and the treatment of uncertainty. We propose a systematic mapping review to characterise the peer-reviewed evidence base and identify methodological gaps relevant to health technology assessment and policy-making. This systematic mapping review aims to: (1) systematically catalogue the published, peer-reviewed evidence and the methodological approaches used in economic evaluations of modern radiotherapy; (2) identify methodological trends, including the uptake and implementation of value of information analysis and (3) highlight evidence gaps by tumour type, geographical region and methodological approach. Methods and analysis: Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, we searched PubMed (MEDLINE), Embase, Scopus, Web of Science Core Collection and EconLit for economic evaluations of radiotherapy published from 2005 onwards, with an initial search on 24 February 2026 and a planned search update before synthesis. Study selection is ongoing; extraction and quality appraisal in duplicate have not been undertaken and no results are reported. Reporting completeness, methodological limitations and uncertainty will be appraised as three separate dimensions using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist, the Bias in Economic Evaluation (ECOBIAS) checklist and the TRansparent Uncertainty ASsessmenT (TRUST) framework, applied descriptively and not combined into a single quality score. Methodological information will be extracted, including model structure (eg, Markov model), analytical perspective (eg, healthcare payer), time horizon, costing approach (eg, diagnosis-related group (DRG)-based) and utility measurement (eg, EQ-5D). The methods used to assess uncertainty will be mapped for all studies, with the ECOBIAS checklist and the TRUST framework only applied to decision-analytic model-based evaluations. Findings will be synthesised descriptively as an evidence gap map and visualised as heat maps and bubble plots. A conceptual co-occurrence network, analysed in R with visualisation in VOSviewer, will map how modalities, tumour sites and economic characteristics cluster across studies. No meta-analysis is planned, given the expected heterogeneity of our findings. Ethics and dissemination: This review does not require ethical approval, as it will use data from previously published studies. The results will be disseminated through peer-reviewed publications, conference presentations and open-access releases of data extraction files and visual maps in the Open Science Framework (OSF). Registration: This review protocol was prospectively registered (9 February 2026) in the OSF Registries (DOI: 10.17605/OSF.IO/6W2TJ).
- Open Access
- 6 August 2026
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 24 (1)
Economic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenance
- 6 August 2026
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 24 (1)
Open AccessEconomic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenance
- Open Access
- 23 June 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1830-1848
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study
The efficacy of adjuvant chemotherapy (AC) in improving survival for patients with sarcoma is debated. We performed a cost-effectiveness analysis (CEA) comparing AC vs. no AC for non-metastatic sarcoma based on the nationwide retrospective study DEEPSARC. The CEA was carried out over a 1-, 3-, and five-year horizon, using data from the French NETSARC+ database linked to the French national health data system (SNDS).There was no age limit and no specific histological type selection in the reference case analysis. Costs (expressed in 2021 EUR) were provided by the SNDS from the French national health insurance perspective. Incremental cost effectiveness ratios (ICER) were expressed in cost per life-year gained (LYG). Propensity score analysis with 1:1 matching was undertaken. Sensitivity and subgroup analyses were performed. Of the 33,548 patients from the French NETSARC+ database, 24,539 were linked to the SNDS. A total of 14,808 patients diagnosed between 2012 and 2017 were included in the reference case analysis with 2,784 patients after propensity score matching. Mean costs (SD) [95% CI] differences per patient between AC and no AC were €12,826 (36,758) [10,883-14,719], €15,706 (49,849) [13,330-18,383], and €16,841 (56,060) [13,590-19,657] at 1, 3, and 5 years, respectively. Mean overall survival differences per patient (in years) were 0.0066 (0.1685) [-0.0021 to 0.0157], -0.0728 (0.9336) [-0.1237 to -0.0229], and -0.1204 (1.3595) [-0.1926 to -0.0475] at 1, 3, and 5 years, respectively. ICER was €1,934,511 [-11,767,351-15,829,959] per LYG at 1 year. AC lagged behind at 3 and 5 years. In the reference case analysis, AC outperformed its use in terms of outcomes at 1 year, but a high level of willingness to pay would be required for AC to be cost-effective. At 3 and 5 years, AC was deemed to be not cost-effective for patients with non-metastatic sarcoma.
- 23 June 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1830-1848
Open AccessEconomic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study
The efficacy of adjuvant chemotherapy (AC) in improving survival for patients with sarcoma is debated. We performed a cost-effectiveness analysis (CEA) comparing AC vs. no AC for non-metastatic sarcoma based on the nationwide retrospective study DEEPSARC. The CEA was carried out over a 1-, 3-, and five-year horizon, using data from the French NETSARC+ database linked to the French national health data system (SNDS).There was no age limit and no specific histological type selection in the reference case analysis. Costs (expressed in 2021 EUR) were provided by the SNDS from the French national health insurance perspective. Incremental cost effectiveness ratios (ICER) were expressed in cost per life-year gained (LYG). Propensity score analysis with 1:1 matching was undertaken. Sensitivity and subgroup analyses were performed. Of the 33,548 patients from the French NETSARC+ database, 24,539 were linked to the SNDS. A total of 14,808 patients diagnosed between 2012 and 2017 were included in the reference case analysis with 2,784 patients after propensity score matching. Mean costs (SD) [95% CI] differences per patient between AC and no AC were €12,826 (36,758) [10,883-14,719], €15,706 (49,849) [13,330-18,383], and €16,841 (56,060) [13,590-19,657] at 1, 3, and 5 years, respectively. Mean overall survival differences per patient (in years) were 0.0066 (0.1685) [-0.0021 to 0.0157], -0.0728 (0.9336) [-0.1237 to -0.0229], and -0.1204 (1.3595) [-0.1926 to -0.0475] at 1, 3, and 5 years, respectively. ICER was €1,934,511 [-11,767,351-15,829,959] per LYG at 1 year. AC lagged behind at 3 and 5 years. In the reference case analysis, AC outperformed its use in terms of outcomes at 1 year, but a high level of willingness to pay would be required for AC to be cost-effective. At 3 and 5 years, AC was deemed to be not cost-effective for patients with non-metastatic sarcoma.
- Open Access
Systematic referral to palliative care in patients attending dedicated emergency units from French comprehensive anticancer centres: the prospective multicentre randomised comparative clinical trial PALLU
Introduction International medical oncology societies recommended early integration of palliative care to alleviate symptoms, improve quality of life and significantly reduce aggressiveness of care near the end of life, defined as the use of chemotherapy, high rate of hospitalisation/visits to emergency or intensive care unit in the last month of life or death in acute care unit. However, the most appropriate schedule for patient referral is still to be determined. Scores and criteria are debated, with uncontrolled symptoms (pain, dyspnoea, distress, etc) being one of the main indicators. These symptoms are also the leading causes for patients with cancer to seek care in emergency units. Several studies in North America suggested that referral to palliative care from emergency units is feasible and efficient. The aim of this study is to determine if systematic early referral to palliative care in a context of emergency reduces aggressiveness of care near the end of life compared with referral on medical team request. Methods and analysis This multicentric randomised study plans to enrol patients with a PALLIA-10 score >3 attending unscheduled on-site visits in French comprehensive cancer centres, and allocate them to randomisation (1:1) to receive palliative care systematically (experimental group) or on medical oncology team request (standard group). The primary objective is to compare the proportion of patients meeting at least one criterion of clinical care aggressiveness near the end of life, in each group. Secondary objectives include a description of clinical care aggressiveness components, palliative care requirement (psychologist, social worker, nutritional counselling, etc), patient-reported outcomes (FACT-G7, Hospital Anxiety and Depression Scale, Edmonton Symptoms Assessment System), the place of death and overall survival. Health economics and human and social sciences substudies will be presented. The study needs to include 192 patients (96 patients per arm) to reach a 20% decrease in care aggressiveness in the last month of life from 65% to 45%, with a statistical power of 80%, and a 2-sided type I error rate of 5%, using systematic referral. Considering a 20% rate of dropout or patients still alive at the time of analysis, 240 patients will need to be allocated to randomisation. Ethics and dissemination This clinical study received approval from the Ethics committee CPP Est III on 25 October 2023, and complies with the MR001 Commission Nationale de l’Informatique et des Libertés (#1994173, 27 September 2016). The first consent was signed on 12 September 2024. Results will be presented and published in international academic journals. Protocol identifier V.2.1 dated 10 July 2024. Trial registration number NCT06150027.
Open AccessSystematic referral to palliative care in patients attending dedicated emergency units from French comprehensive anticancer centres: the prospective multicentre randomised comparative clinical trial PALLU
Introduction International medical oncology societies recommended early integration of palliative care to alleviate symptoms, improve quality of life and significantly reduce aggressiveness of care near the end of life, defined as the use of chemotherapy, high rate of hospitalisation/visits to emergency or intensive care unit in the last month of life or death in acute care unit. However, the most appropriate schedule for patient referral is still to be determined. Scores and criteria are debated, with uncontrolled symptoms (pain, dyspnoea, distress, etc) being one of the main indicators. These symptoms are also the leading causes for patients with cancer to seek care in emergency units. Several studies in North America suggested that referral to palliative care from emergency units is feasible and efficient. The aim of this study is to determine if systematic early referral to palliative care in a context of emergency reduces aggressiveness of care near the end of life compared with referral on medical team request. Methods and analysis This multicentric randomised study plans to enrol patients with a PALLIA-10 score >3 attending unscheduled on-site visits in French comprehensive cancer centres, and allocate them to randomisation (1:1) to receive palliative care systematically (experimental group) or on medical oncology team request (standard group). The primary objective is to compare the proportion of patients meeting at least one criterion of clinical care aggressiveness near the end of life, in each group. Secondary objectives include a description of clinical care aggressiveness components, palliative care requirement (psychologist, social worker, nutritional counselling, etc), patient-reported outcomes (FACT-G7, Hospital Anxiety and Depression Scale, Edmonton Symptoms Assessment System), the place of death and overall survival. Health economics and human and social sciences substudies will be presented. The study needs to include 192 patients (96 patients per arm) to reach a 20% decrease in care aggressiveness in the last month of life from 65% to 45%, with a statistical power of 80%, and a 2-sided type I error rate of 5%, using systematic referral. Considering a 20% rate of dropout or patients still alive at the time of analysis, 240 patients will need to be allocated to randomisation. Ethics and dissemination This clinical study received approval from the Ethics committee CPP Est III on 25 October 2023, and complies with the MR001 Commission Nationale de l’Informatique et des Libertés (#1994173, 27 September 2016). The first consent was signed on 12 September 2024. Results will be presented and published in international academic journals. Protocol identifier V.2.1 dated 10 July 2024. Trial registration number NCT06150027.
- Open Access
- 3 February 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 193, 110116
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial
- 3 February 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 193, 110116
Open AccessCost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial
- Open Access
- 21 July 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Automation Science and Engineering
- Vol. 21 (3) , 4364-4381
Optimal Process Mining of Traces With Events and Transition Attributes With Application to Care Pathways of Cancer Patients
Contrary to event traces considered in traditional process mining literature, this paper addresses the problem of optimal process mining of traces of events and attributes associated with transitions. The problem is formally defined with rigorous description of the input event logs, the output process model, the event game specifying the images of traces in the model, and a non standard quality metric termed relevance for both the model and all model components. A dynamic programming algorithm is proposed to determine the optimal event game of each trace for a given process model. A multi-start local optimization algorithm built on an original concept of marginal relevance measure is developed for process model optimization. The proposed algorithm is shown to outperform benchmark algorithms on 40 generated test instances and be able to produce near optimal process model with an optimality gap of less than 4.46%. Results of this paper are also applied to a real case study of the care pathways of sarcoma patients. The event log representation is shown to be able to describe accurately the impact of the health state on the care pathways with only minor model relevance degradation. The proposed approach is shown to be able to generate process model at various precision levels and to compare the care pathways of cancer patients. It is also shown to generate better process model than the widely used process mining tools Disco and DFvM on both our relevance and the traditional fitness quality metrics. Note to Practitioners —This paper is motivated by our collaboration with the French cancer centre (Centre Léon Bérard) on data-driven modeling of sarcoma patient care pathways. The primary goal is to investigate the impact of patient health state such as cancer progression on the care pathways. We achieve this by original representation of care pathways by traces of events interleaved by health states. The original concept of “relevance” clearly measures the importance of each element in the process model. The faithfulness of the process model and its complexity can be easily controlled by precision parameters including least significance level of each model element and the number of layers of the model. A case study of Sarcoma patients is presented to show the importance of our care pathway representation, the superiority of our process mining algorithm, the difference of care pathways of four different patient management strategies, and how the health condition intervenes in different strategies.
- 21 July 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Automation Science and Engineering
- Vol. 21 (3) , 4364-4381
Open AccessOptimal Process Mining of Traces With Events and Transition Attributes With Application to Care Pathways of Cancer Patients
Contrary to event traces considered in traditional process mining literature, this paper addresses the problem of optimal process mining of traces of events and attributes associated with transitions. The problem is formally defined with rigorous description of the input event logs, the output process model, the event game specifying the images of traces in the model, and a non standard quality metric termed relevance for both the model and all model components. A dynamic programming algorithm is proposed to determine the optimal event game of each trace for a given process model. A multi-start local optimization algorithm built on an original concept of marginal relevance measure is developed for process model optimization. The proposed algorithm is shown to outperform benchmark algorithms on 40 generated test instances and be able to produce near optimal process model with an optimality gap of less than 4.46%. Results of this paper are also applied to a real case study of the care pathways of sarcoma patients. The event log representation is shown to be able to describe accurately the impact of the health state on the care pathways with only minor model relevance degradation. The proposed approach is shown to be able to generate process model at various precision levels and to compare the care pathways of cancer patients. It is also shown to generate better process model than the widely used process mining tools Disco and DFvM on both our relevance and the traditional fitness quality metrics. Note to Practitioners —This paper is motivated by our collaboration with the French cancer centre (Centre Léon Bérard) on data-driven modeling of sarcoma patient care pathways. The primary goal is to investigate the impact of patient health state such as cancer progression on the care pathways. We achieve this by original representation of care pathways by traces of events interleaved by health states. The original concept of “relevance” clearly measures the importance of each element in the process model. The faithfulness of the process model and its complexity can be easily controlled by precision parameters including least significance level of each model element and the number of layers of the model. A case study of Sarcoma patients is presented to show the importance of our care pathway representation, the superiority of our process mining algorithm, the difference of care pathways of four different patient management strategies, and how the health condition intervenes in different strategies.
- Open Access
Multicentre, randomised, economic evaluation of a web-based interactive education platform, simple or enhanced, for patients with end-stage renal disease: the PIC-R trial protocol
Introduction End-stage renal disease (ESRD) affects 84 000 persons in France and costs an estimated €4.2 billion. Education about their disease empowers patients and allows improved management of their disease and better health outcomes. This study aims to explore whether the addition of an interactive web-based platform to patient education is effective and cost-effective and additionally whether complementing the platform with social functions and features improves its performance. Methods and analysis Patients with severe, ESRD or post-transplant will be randomised 1:1:1 to either standard therapeutic education; or education using a specific application; or the enhanced interactive app with social features. The total follow-up duration is 18 months. Primary endpoint is the cost utility of using app-based therapeutic intervention; secondary endpoints are: compliance with treatment guidelines, app use (professionals and patients), patients’ satisfaction, budget impact analysis. Ethics and dissemination The findings will inform the deployment and reimbursement of the application. The study has ethical approval by the Ile de France ethics committee. Dissemination of the results will be presented at conferences and in peer-reviewed publications. Trial registration number NCT03090828.
Open AccessMulticentre, randomised, economic evaluation of a web-based interactive education platform, simple or enhanced, for patients with end-stage renal disease: the PIC-R trial protocol
Introduction End-stage renal disease (ESRD) affects 84 000 persons in France and costs an estimated €4.2 billion. Education about their disease empowers patients and allows improved management of their disease and better health outcomes. This study aims to explore whether the addition of an interactive web-based platform to patient education is effective and cost-effective and additionally whether complementing the platform with social functions and features improves its performance. Methods and analysis Patients with severe, ESRD or post-transplant will be randomised 1:1:1 to either standard therapeutic education; or education using a specific application; or the enhanced interactive app with social features. The total follow-up duration is 18 months. Primary endpoint is the cost utility of using app-based therapeutic intervention; secondary endpoints are: compliance with treatment guidelines, app use (professionals and patients), patients’ satisfaction, budget impact analysis. Ethics and dissemination The findings will inform the deployment and reimbursement of the application. The study has ethical approval by the Ile de France ethics committee. Dissemination of the results will be presented at conferences and in peer-reviewed publications. Trial registration number NCT03090828.
- Open Access
- 20 May 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (5) , e32002
How We Can Reap the Full Benefit of Teleconsultations: Economic Evaluation Combined With a Performance Evaluation Through a Discrete-Event Simulation
Background: In recent years, the rapid development of information and communications technology enabled by innovations in videoconferencing solutions and the emergence of connected medical devices has contributed to expanding the scope of application and expediting the development of telemedicine. Objective: This study evaluates the use of teleconsultations (TCs) for specialist consultations at hospitals in terms of costs, resource consumption, and patient travel time. The key feature of our evaluation framework is the combination of an economic evaluation through a cost analysis and a performance evaluation through a discrete-event simulation (DES) approach. Methods: Three data sets were used to obtain detailed information on the characteristics of patients, characteristics of patients’ residential locations, and usage of telehealth stations. A total of 532 patients who received at least one TC and 18,559 patients who received solely physical consultations (CSs) were included in the initial sample. The TC patients were recruited during a 7-month period (ie, 2020 data) versus 19 months for the CS patients (ie, 2019 and 2020 data). A propensity score matching procedure was applied in the economic evaluation. To identify the best scenarios for reaping the full benefits of TCs, various scenarios depicting different population types and deployment strategies were explored in the DES model. Associated break-even levels were calculated. Results: The results of the cost evaluation reveal a higher cost for the TC group, mainly induced by higher volumes of (tele)consultations per patient and the substantial initial investment required for TC equipment. On average, the total cost per patient over 298 days of follow-up was €356.37 (US $392) per TC patient and €305.18 (US $336) per CS patient. However, the incremental cost of TCs was not statistically significant: €356.37 – €305.18 = €51.19 or US $392 – US $336 = US $56 (95% CI –35.99 to 114.25; P=.18). Sensitivity analysis suggested heterogeneous economic profitability levels within subpopulations and based on the intensity of use of TC solutions. In fact, the DES model results show that TCs could be a cost-saving strategy in some cases, depending on population characteristics, the amortization speed of telehealth equipment, and the locations of telehealth stations. Conclusions: The use of TCs has the potential to lead to a major organizational change in the health care system in the near future. Nevertheless, TC performance is strongly related to the context and deployment strategy involved.
- 20 May 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (5) , e32002
Open AccessHow We Can Reap the Full Benefit of Teleconsultations: Economic Evaluation Combined With a Performance Evaluation Through a Discrete-Event Simulation
Background: In recent years, the rapid development of information and communications technology enabled by innovations in videoconferencing solutions and the emergence of connected medical devices has contributed to expanding the scope of application and expediting the development of telemedicine. Objective: This study evaluates the use of teleconsultations (TCs) for specialist consultations at hospitals in terms of costs, resource consumption, and patient travel time. The key feature of our evaluation framework is the combination of an economic evaluation through a cost analysis and a performance evaluation through a discrete-event simulation (DES) approach. Methods: Three data sets were used to obtain detailed information on the characteristics of patients, characteristics of patients’ residential locations, and usage of telehealth stations. A total of 532 patients who received at least one TC and 18,559 patients who received solely physical consultations (CSs) were included in the initial sample. The TC patients were recruited during a 7-month period (ie, 2020 data) versus 19 months for the CS patients (ie, 2019 and 2020 data). A propensity score matching procedure was applied in the economic evaluation. To identify the best scenarios for reaping the full benefits of TCs, various scenarios depicting different population types and deployment strategies were explored in the DES model. Associated break-even levels were calculated. Results: The results of the cost evaluation reveal a higher cost for the TC group, mainly induced by higher volumes of (tele)consultations per patient and the substantial initial investment required for TC equipment. On average, the total cost per patient over 298 days of follow-up was €356.37 (US $392) per TC patient and €305.18 (US $336) per CS patient. However, the incremental cost of TCs was not statistically significant: €356.37 – €305.18 = €51.19 or US $392 – US $336 = US $56 (95% CI –35.99 to 114.25; P=.18). Sensitivity analysis suggested heterogeneous economic profitability levels within subpopulations and based on the intensity of use of TC solutions. In fact, the DES model results show that TCs could be a cost-saving strategy in some cases, depending on population characteristics, the amortization speed of telehealth equipment, and the locations of telehealth stations. Conclusions: The use of TCs has the potential to lead to a major organizational change in the health care system in the near future. Nevertheless, TC performance is strongly related to the context and deployment strategy involved.
- 1 December 2021
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (12) , 1162-1169
Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
- 1 December 2021
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (12) , 1162-1169
Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
- 1 December 2021
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (12) , 1170-1180
How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
- 1 December 2021
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (12) , 1170-1180
How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?